MX2021012313A - Formas cristalinas de un inhibidor de trpc de piridazinona. - Google Patents

Formas cristalinas de un inhibidor de trpc de piridazinona.

Info

Publication number
MX2021012313A
MX2021012313A MX2021012313A MX2021012313A MX2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A
Authority
MX
Mexico
Prior art keywords
inhibitor
trpc
pyridazinone
crystal forms
compound
Prior art date
Application number
MX2021012313A
Other languages
English (en)
Spanish (es)
Inventor
Wenfeng Xue
Yuejun Gao
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MX2021012313A publication Critical patent/MX2021012313A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2021012313A 2019-04-10 2020-04-10 Formas cristalinas de un inhibidor de trpc de piridazinona. MX2021012313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Publications (1)

Publication Number Publication Date
MX2021012313A true MX2021012313A (es) 2021-11-17

Family

ID=70482847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012313A MX2021012313A (es) 2019-04-10 2020-04-10 Formas cristalinas de un inhibidor de trpc de piridazinona.
MX2025006384A MX2025006384A (es) 2019-04-10 2021-10-07 Formas cristalinas de un inhibidor de trpc de piridazinona

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025006384A MX2025006384A (es) 2019-04-10 2021-10-07 Formas cristalinas de un inhibidor de trpc de piridazinona

Country Status (10)

Country Link
US (1) US20220177455A1 (https=)
EP (1) EP3953352A1 (https=)
JP (2) JP7738482B2 (https=)
CN (2) CN114502552B (https=)
AU (1) AU2026201003A1 (https=)
BR (1) BR112021018221A2 (https=)
CA (1) CA3136652A1 (https=)
MA (1) MA55614A (https=)
MX (2) MX2021012313A (https=)
WO (2) WO2020206623A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
US12576033B2 (en) * 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ,インク. 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
JP7539545B2 (ja) * 2020-07-03 2024-08-23 武漢朗来科技発展有限公司 複素環化合物及びその使用
US20250122190A1 (en) * 2021-09-10 2025-04-17 Medshine Discovery Inc. Halogen-substituted pyridazinone compound and application thereof
US20250082655A1 (en) * 2022-01-27 2025-03-13 Wuhan Createrna Science And Technology Co., Ltd. Use of heterocyclic compound
WO2024027752A1 (zh) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
AU2020272030B2 (en) 2025-11-13
AU2020272030A1 (en) 2021-11-11
CN114502552A (zh) 2022-05-13
AU2026201003A1 (en) 2026-03-05
MX2025006384A (es) 2025-07-01
JP2022525759A (ja) 2022-05-19
CN119264134A (zh) 2025-01-07
EP3953352A1 (en) 2022-02-16
MA55614A (fr) 2022-02-16
CN114502552B (zh) 2024-08-16
BR112021018221A2 (pt) 2022-01-18
US20220177455A1 (en) 2022-06-09
WO2020206623A1 (en) 2020-10-15
WO2020210639A1 (en) 2020-10-15
CA3136652A1 (en) 2020-10-15
JP2026004294A (ja) 2026-01-14

Similar Documents

Publication Publication Date Title
MX2021012313A (es) Formas cristalinas de un inhibidor de trpc de piridazinona.
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
SA522431867B1 (ar) مثبطات كيناز بروتين-1 المتفاعل مع المستقبل غير متجانسة الحلقات
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
EP4483881A3 (en) Fused ring compounds
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2021003105A1 (es) Inhibidores de masp-2 y métodos de uso (divisional de la solicitud no. 202003083)
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
EA202092086A1 (ru) Ингибиторы аргиназы
MX2024008551A (es) Terapias de combinacion.
EA202091372A1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
MX2022005256A (es) Inhibidores de cd73.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CO2022000751A2 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
UY37665A (es) Formas cristalinas de (s)-afoxolaner